nifedipine has been researched along with Atherosclerosis in 8 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 7.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris." | 7.74 | Tracking coronary calcification and atherosclerotic lesions in patients with stable angina pectoris undergoing nifedipine therapy. ( de Brouwer, S; Kirwan, BA; Motro, M; Poole-Wilson, PA; Shemesh, J, 2007) |
| " We, along with others, have recently found that nifedipine, one of the most widely used DHPs, inhibits apoptotic cell death of endothelial cells (ECs) as well as vascular inflammation and subsequently improves endothelial function in patients with cardiovascular risk factors, including hypertension and/or diabetes, thus slowing the development and progression of atherosclerosis in these patients." | 4.84 | Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. ( Matsui, T; Nakamura, K; Yamagishi, S, 2008) |
| "Nifedipine, an L-type calcium channel blocker, protects against the progression of atherosclerosis." | 3.76 | Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice. ( Araki, E; Fukuda, K; Ishii, N; Kawada, T; Kim-Mitsuyama, S; Kinoshita, H; Matsumura, T; Miyamura, N; Motoshima, H; Nakao, S; Nishikawa, T; Senokuchi, T; Takeya, M; Tsutsumi, A, 2010) |
| "Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris." | 3.74 | Tracking coronary calcification and atherosclerotic lesions in patients with stable angina pectoris undergoing nifedipine therapy. ( de Brouwer, S; Kirwan, BA; Motro, M; Poole-Wilson, PA; Shemesh, J, 2007) |
| "Atherosclerosis is the main underlying pathology of cardiovascular disease." | 2.44 | Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects. ( Chan, KC; Lin, CS; Lin, MC; Ueng, KC, 2007) |
| "Nifedipine treatment substantially reduced lipid accumulation and the expression of CD36, SR-A, and protein kinase C (PKC)-θ in human macrophages treated with ox-LDL." | 1.42 | Nifedipine inhibits ox-LDL-induced lipid accumulation in human blood-derived macrophages. ( Sha Ma, AZ; Song, ZY; Tang, WQ; Wang, C; Zhang, Q, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Q | 1 |
| Sha Ma, AZ | 1 |
| Wang, C | 1 |
| Tang, WQ | 1 |
| Song, ZY | 1 |
| Chen, TH | 1 |
| Shih, CY | 1 |
| Hsu, WL | 1 |
| Chou, TC | 1 |
| Kawamoto, B | 1 |
| Shimizu, S | 1 |
| Shimizu, T | 1 |
| Higashi, Y | 1 |
| Hikita, K | 1 |
| Muraoka, K | 1 |
| Honda, M | 1 |
| Sejima, T | 1 |
| Takenaka, A | 1 |
| Saito, M | 1 |
| Ishii, N | 1 |
| Matsumura, T | 1 |
| Kinoshita, H | 1 |
| Fukuda, K | 1 |
| Motoshima, H | 1 |
| Senokuchi, T | 1 |
| Nakao, S | 1 |
| Tsutsumi, A | 1 |
| Kim-Mitsuyama, S | 1 |
| Kawada, T | 1 |
| Takeya, M | 1 |
| Miyamura, N | 1 |
| Nishikawa, T | 1 |
| Araki, E | 1 |
| Yamagishi, S | 2 |
| Nakamura, K | 2 |
| Takenaka, K | 1 |
| Matsui, T | 2 |
| Inoue, H | 1 |
| Motro, M | 1 |
| Kirwan, BA | 1 |
| de Brouwer, S | 1 |
| Poole-Wilson, PA | 1 |
| Shemesh, J | 1 |
| Ueng, KC | 1 |
| Lin, MC | 1 |
| Chan, KC | 1 |
| Lin, CS | 1 |
3 reviews available for nifedipine and Atherosclerosis
| Article | Year |
|---|---|
Pleiotropic effects of nifedipine on atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Calcium Channel Blockers; Endothe | 2006 |
Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects.
Topics: Animals; Atherosclerosis; Calcium Channel Blockers; Clinical Trials as Topic; Delayed-Action Prepara | 2007 |
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Calcium Channels; Cardiovascular Diseases; Cytokines; Diab | 2008 |
5 other studies available for nifedipine and Atherosclerosis
| Article | Year |
|---|---|
Nifedipine inhibits ox-LDL-induced lipid accumulation in human blood-derived macrophages.
Topics: Atherosclerosis; Calcium Channel Blockers; CD36 Antigens; Cells, Cultured; Humans; Isoenzymes; Lipid | 2015 |
Mechanisms of Nifedipine-Downregulated CD40L/sCD40L Signaling in Collagen Stimulated Human Platelets.
Topics: Atherosclerosis; Blood Platelets; Calcium Channel Blockers; CD40 Ligand; Cells, Cultured; Drug Evalu | 2015 |
Vesicovascular reflexes in the spontaneously hypertensive rat.
Topics: Animals; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Blood Vessels; Epinephrine; Hyper | 2016 |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
Topics: Amlodipine; Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Bin | 2010 |
Tracking coronary calcification and atherosclerotic lesions in patients with stable angina pectoris undergoing nifedipine therapy.
Topics: Aged; Angina Pectoris; Atherosclerosis; Calcinosis; Calcium Channel Blockers; Coronary Vessels; Fema | 2007 |